title: Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.
abstract: Ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor, which has recently gained approval by the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with symptomatic Waldenström macroglobulinemia (WM). Herein, we review the role of BTK in the pathophysiology of WM, and present the results of the preclinical and clinical studies that led to the initial investigation and later approval of ibrutinib in WM. We also discuss aspects associated with ibrutinib therapy in WM patients, especially focusing on genomic profiling and the impact on response to ibrutinib, and the management of adverse events.
authors: Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA.
authors: Jorge J
authors: JJ
authors: Castillo
authors: Division of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors: M Lia
authors: ML
authors: Palomba
authors: Division of Oncology, Stanford University Medical Center, Stanford University, Stanford, CA, USA.
authors: Ranjana
authors: R
authors: Advani
authors: Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors: Steven P
authors: SP
authors: Treon
keywords: Bruton’s tyrosine kinase; Waldenström macroglobulinemia; ibrutinib; lymphoplasmacytic lymphoma